A study published in JAMA Network Open suggested that there is no link between the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and pancreatic cancer risk among adults with type 2 diabetes over a period of up to 7 years. The researchers conducted a cohort study on over 500,000 participants and found no significant increase in the risk of pancreatic cancer associated with GLP-1RA use compared to basal insulin use. They concluded that there is no excess risk of pancreatic cancer associated with GLP-1RA treatment in patients with type 2 diabetes, although monitoring for pancreatic cancer risk beyond 7 years following therapy initiation is still necessary.
Source link
GLP-1RAs and Pancreatic Cancer Unrelated Among Type 2 Diabetes Patients
